LX7101 is a pyrrolopyrimidine-based, topically-delivered inhibitor of LIM domain kinase 2 (LIMK2), a kinase associated with the regulation of intraocular pressure. LX7101 acts by enhancing fluid outflow through the trabecular meshwork of the eye. Preclinical studies indicate that LX7101 significantly reduced intraocular pressure in both mouse and monkey models. [1] LX7101 recently completed a randomized, double-blind, placebo-controlled Phase 1/2a trial for patients with open angle glaucoma or ocular hypertension. [2]
Technical information:
| Chemical Formula: | C23H30ClN7O3 | |
| CAS #: | 1192189-69-7 | |
| Molecular Weight: | 487.98 | |
| Purity: | >98% | |
| Appearance: | White | |
| Chemical Name: | 3-(4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate hydrochloride | |
| Solubility: | Up to 20 mM in DMSO | |
| Synonyms: | LX-7101, LX7101 |
Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.
Reference:
| 1. | Lexicon Genetics webpage |
| 2. | www.clinicaltrials.gov webpage for LX7101 Phase 1/2a trials (completed 8/12) |
Other Information:
Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.
